Nexium Over the Counter (OTC)

Posted on Posted in Pharmacy Benefits Industry Updates


Nexium, a popular medication used for heartburn became available over the counter (OTC) on May 27, 2014. With 2013 global sales of prescription Nexium that reached $7.8 billion and ranked 6th in sales volume worldwide, its OTC availability presents an excellent opportunity for cost savings.

Let Solid Benefit Guidance help you manage these and other changing market dynamics that affect your bottom line.  Contact Us Today to find out more.

Nexium belongs to a category of medications called Proton pump inhibitors (PPIs). PPIs reduce stomach acid production and used by many individuals to relieve heartburn symptoms and/or for treatment of other gastrointestinal conditions. For most people, these medications provide similar relief from acid-related symptoms. Nexium joins the ranks of several PPI medications that are already available as OTC products. See Table 1 below.  Four of the six PPIs are available over the counter. Additionally, four PPIs have prescription generic equivalents. Dexilant is the only PPI that does not have either a prescription generic equivalent or availability over-the-counter.

Read More

Copaxone (glatiramer acetate injection) 40mg – Formulary or Nonformulary?

Posted on Posted in Pharmacy Benefits Industry Updates


In January 2014, Teva announced the FDA approval of a subcutaneous three times-a-week formulation of Copaxone 40mg/mL, as another option to its 20mg once daily formulation. This came at a crucial time of the much anticipated generic availability of Teva’s daily Copaxone 20 mg/mL product that was set to become available in May 2014.

Let Solid Benefit Guidance help you manage these and other changing market dynamics that affect your bottom line.  Contact Us today to find out more.

This date has come and gone with the generic availability mainly dependent on FDA generic drug approvals and the capacity of the generic filer Momenta Pharmaceuticals and its partner Sandoz to launch its product when the approval is received. It is uncertain if Teva will be successful in staving off generics by persuading the FDA to require additional clinical studies for approval. Teva estimates about $78 million in sales for every month that Copaxone keeps its exclusivity. For now, it is a waiting game to see if/when generic Copaxone comes to market and how many companies will launch.

Read More

Rising Cost of Prescription Compounds

Posted on Posted in Pharmacy Benefits Industry Updates


The rising cost of compound prescription drugs is becoming an element of focus among health care payers.

Let Solid Benefit Guidance help you manage these and other changing market dynamics that affect your bottom line.  Contact Us today to find out more.

According to one national prescription drug benefit manager (PBM), costs of compounded prescriptions have risen over the past two years, with observations of payers experiencing up to a 218% average increase in CY2013 in year over year drug spend on compounded medications. The average per claim costs rose from $98 to $195.  

Read More

Drug Flash Report Hep C

Posted on Posted in Pharmacy Benefits Industry Updates

Solid Benefit Guidance offers perspectives to our clients on key therapies, which impact prescription medication spend and/or provide significant improvements in treatment options. This includes consideration of the most up-to-date scientific information, regulatory guidance, national treatment guidelines and practical considerations, in the development of sound utilization management coverage policies and criteria that reflect the client’s philosophy in applying best practice approaches for medication management.

Read More

Drug Flash Report Zohydro

Posted on Posted in Pharmacy Benefits Industry Updates

On December 17, 2013, the Centers for Medicare and Medicaid Services (CMS) issued a memorandum to all Medicare Part D Plan Sponsors encouraging the use of utilization management on a newly approved long-acting hydrocodone medication product, Zohydro™ ER.

Read More